Loading
A phase 3 trial of Aglatimagene besadenovec in prostate cancer, run by Candel Therapeutics, Inc., active and no longer recruiting.
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer is a phase 3 interventional study registered as NCT01436968 by Candel Therapeutics, Inc., with 711 participants planned, started 2011-09 and due to reach its primary completion in 2024-08. Interventions recorded: Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Aglatimagene besadenovec, Candel Therapeutics, Prostate cancer.
Shares Aglatimagene besadenovec, Candel Therapeutics, Prostate cancer.